Extended Data Fig. 3: Duration of response (double-blind ITT population). | Nature Cancer

Extended Data Fig. 3: Duration of response (double-blind ITT population).

From: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Extended Data Fig. 3

Kaplan–Meier estimates of duration of response (investigator assessed) in patients with metastatic NSCLC without known sensitising mutations, treated with sugemalimab plus chemotherapy (sugemalimab group, N = 203 patients) or placebo plus chemotherapy (placebo group, N = 64 patients). CI, confidence interval; NSCLC, non-small-cell lung cancer.

Source data

Back to article page